2020Leading paths to innovation12.
Conclusion of a distributorship agreements with 12 global partners
Attending 2020 AACC, virtual exhibition
Participated as a sponsor in the 2020 Autumn Symposium of the Korean Society of Genetic Diagnostics.
Listed on Korean Stock Exchange market (KOSDAQ: 354200)11.
Attending 2020 MEDICA, virtual exhibition
Attending Omnia Health Live America, virtual exhibition10.
Attending Bio Health Worldwide online exhibition
Attending Omnia Health Live Africa, virtual exhibition08.
ISO/IEC 27001:2013 certificated cloud based NGeneAnalySys™07.
COVID-19 detection kit (NGenePlex™ nCoV qRT-PCR Kit) CE-IVD registeredand MFDS Export Approval04.
NGS panel for solid tumor (SOLIDaccuTest™ DNA) CE-IVD registered
Attending 2020 MEDLAB, Dubai
Conclusion of a distributorship agreement with 7 partners
ISO 13485:2016 certificate11.
Started exporting products to overseas market10.
Attending 2019 MEDICA, Germany08.
BRCA epidemiology study with Samsung Medical Center and 20 big hospitals (metastatic breast cancer patients)06.
Attending 2019 AACC, California USA02.
Attending 2019 MEDLAB, Dubai01.
ISO 9001:2015 certificate received
2018Take off to the world12.
ISO 13485 2016 certificate received11.
HEMEaccuTest™ CE-IVD approved
Attending MEDICA2018 in Düsseldorf, Germany10.
Partnerships with BioMed Global Singapore and Ozgun Kimya A.S. Turkey09.
ISO 9001 certificate received08.
2nd oversea a demonstration of HEMEaccuTest™ and BRCAaccuTest™ PLUS in Singapore
ISO 13485 and ISO 9001 inspection07.
Attending FEME 2018 in Florida and AACC 2018 in Chicago, USA05.
1st oversea demonstration of BRCAaccuTest™ PLUS in Italy
Partnership with AmitisGen Med TECH Group, Iran02.
Attending MEDLAB 2018 in Dubai, UAE
Institutional review board registered for in vitro diagnostic reagent06.
BRCAaccuTest™ & NGeneAnalySys™ CE-IVD approved05.
ISO13485 certificated NGS software04.
Korean Ministry of Food and Drug Safety approved clinical trail for NGS panel02.
GMP certification for NGS software and in vitro diagnosis medical device & quality criterion01.
Acquired ISO 9001, 13485 Certification11.
Contracted development and development of chemotherapy drug development project10.
Acquired GMP certification for in vitro diagnostic reagent08.
Selected for Intellectual Property R&D07.
Genetic Testing Agency Approved06.
Launched NGS based breast cancer panel & S/W (illumina MiSeq & MiSeq Dx), Selected as a project to commercialize fetal genetic diseases05.
Selected as an NGS disease analysis platform commercialization project03.
Designated as a venture enterprise
Built NGS Molecular Laboratory11.
Selected NGS based chemotherapy diagnosis project, the establishment of a company-affiliated research institute10.
Established NGeneBio Co., Ltd.
Established NGeneBio and Spin off
Launched cloud-based genome service, established Korea Telecom company No. 1